Scholar Rock Holding Corporation (SRRK)
Automate Your Wheel Strategy on SRRK
With Tiblio's Option Bot, you can configure your own wheel strategy including SRRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SRRK
- Rev/Share 0.0
- Book/Share 2.7927
- PB 13.0052
- Debt/Equity 0.2022
- CurrentRatio 10.253
- ROIC -0.7195
- MktCap 3448424192.0
- FreeCF/Share -2.0582
- PFCF -14.9811
- PE -15.3767
- Debt/Assets 0.1549
- DivYield 0
- ROE -1.1822
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | SRRK | H.C. Wainwright | -- | Buy | $30 | $35 | Oct. 7, 2024 |
News
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Published: June 18, 2025 by: Benzinga
Sentiment: Positive
Scholar Rock SRRK revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss.
Read More
Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that David L. Hallal, Chief Executive Officer, and members of management will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 11 at 9:20 a.m. ET in Miami, F.
Read More
Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that Rebecca McLeod has been appointed to the newly created role of Chief Brand Officer and U.S. General Manager. In this role, she will be responsible for leading the anticipated U.S. commercial launch of apitegromab fo.
Read More
Scholar Rock Holding Corporation (SRRK) Q1 2025 Earnings Call Transcript
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q1 2025 Earnings Conference Call May 14, 2025 8:15 AM ET Company Participants Rushmie Nofsinger - VP, Corporate Affairs and IR David Hallal - CEO Akshay Vaishnaw - President of R&D Keith Woods - COO Vikas Sinha - CFO Conference Call Participants Allison Bratzel - Piper Sandler Michael Yee - Jefferies Tessa Romero - JPMorgan David Nierengarten - Wedbush Gary Nachman - Raymond James Kripa Devarakonda - Truist Marc Frahm - TD Cowen Andres Maldonado - H.C. Wainwright Dennis Kennedy - LifeSci Capital Operator Ladies and gentlemen, thank you for standing by.
Read More
Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that management will host a conference call to discuss its first quarter 2025 financial results and provide a business update on Wednesday, May 14, 2025, at 8:15am ET. To access the live conference call, participants may register here. The live audio web.
Read More
Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth
Published: April 28, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, announced today that David Hallal has been appointed Chief Executive Officer succeeding Jay Backstrom, M.D. David Hallal has served as Chairman of the Board at Scholar Rock since 2017 and just prior to that spent more than a decade as CEO, COO, and CCO of Alexion buildi.
Read More
Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Scholar Rock Holding Corporation. (NASDAQ:SRRK ) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco - Chief Commercial Officer Conference Call Participants Allison Bratzel - Piper Sandler Michael Yee - Jefferies Tessa Romero - JPMorgan Gary Nachman - Raymond James Operator Good morning and welcome to Scholar Rock's Fourth Quarter Financial Results and Business Update Call.
Read More
About Scholar Rock Holding Corporation (SRRK)
- IPO Date 2018-05-25
- Website https://scholarrock.com
- Industry Biotechnology
- CEO Mr. David L. Hallal
- Employees 128